Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in type 2 diabetes mellitus
NCT06403761Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CagriSema in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Change in M-value in hyperinsulinaemic euglycaemic clamp at 28 weeks. Started May 2024; status: completed.
02
Drugs
CagriSema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06403761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06403761.